- Home
- KROS vs TRML Comparison
KROS vs TRML Comparison
Compare KROS & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- TRML
- Stock Information
- Founded
- KROS 2015
- TRML 2021
- Country
- KROS United States
- TRML United States
- Employees
- KROS N/A
- TRML N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- KROS Health Care
- TRML Health Care
- Exchange
- KROS Nasdaq
- TRML Nasdaq
- Market Cap
- KROS 565.0M
- TRML 598.9M
- IPO Year
- KROS 2020
- TRML N/A
- Fundamental
- Price
- KROS $15.65
- TRML $47.60
- Analyst Decision
- KROS Buy
- TRML Hold
- Analyst Count
- KROS 14
- TRML 10
- Target Price
- KROS $20.56
- TRML $46.85
- AVG Volume (30 Days)
- KROS 445.6K
- TRML 1.5M
- Earning Date
- KROS 11-05-2025
- TRML 11-06-2025
- Dividend Yield
- KROS N/A
- TRML N/A
- EPS Growth
- KROS N/A
- TRML N/A
- EPS
- KROS 0.47
- TRML N/A
- Revenue
- KROS $232,844,000.00
- TRML N/A
- Revenue This Year
- KROS $5,579.44
- TRML N/A
- Revenue Next Year
- KROS N/A
- TRML N/A
- P/E Ratio
- KROS $33.59
- TRML N/A
- Revenue Growth
- KROS 85820.30
- TRML N/A
- 52 Week Low
- KROS $9.12
- TRML $11.56
- 52 Week High
- KROS $72.37
- TRML $47.69
- Technical
- Relative Strength Index (RSI)
- KROS 59.98
- TRML 94.39
- Support Level
- KROS $15.25
- TRML $22.31
- Resistance Level
- KROS $16.00
- TRML $47.69
- Average True Range (ATR)
- KROS 0.61
- TRML 1.34
- MACD
- KROS 0.03
- TRML 2.42
- Stochastic Oscillator
- KROS 78.77
- TRML 99.65
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.